FIG 2.

The association between high TMB status and survival after anti-PD1/PDL1 treatment for male and female patients separately in seven cancer types. (A) Standard box plots displaying the distribution of log₁₀(TMB) (x-axis) for male and female patients across cancer types (y-axis) in a similar manner to Figure 1A. (B) HRs of patients with high TMB (≥ 10 mutation/Mb) versus the rest (x-axis) in each cancer type (y-axis), sex color code as in (A), displayed in a similar manner to that of Figure 1B. Renal cell carcinoma is not reported in our analysis as its HR cannot be computed confidently. HR, hazard ratio; NSCLC, non–small-cell lung cancer; PD1, programmed cell death protein 1; PDL1, programmed death-ligand 1; TMB, tumor mutational burden.